Ebola vaccine trial aims to shield frontline workers in congo
NCT ID NCT04186000
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This study tests a two-dose Ebola vaccine regimen in healthcare workers in the Democratic Republic of the Congo, who are at high risk during outbreaks. Participants receive an initial shot of Ad26.ZEBOV followed by a booster of MVA-BN-Filo 56 days later. Some will also get an additional booster at one or two years. The goal is to measure the immune response and monitor safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a two-dose Ebola vaccine regimen: Ad26.ZEBOV followed by MVA-BN-Filo, with a possible booster of Ad26.ZEBOV at 1 or 2 years
- What this could lead to
- If successful, this vaccine regimen could help protect healthcare workers against Ebola, reducing the risk of outbreaks spreading in high-risk areas.
- What could go wrong
- This is a phase 2 study, so the vaccine's effectiveness and long-term safety are still being evaluated. The immune response may not be strong enough to prevent infection, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBOLA VIRUS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Général de Référence de Boende
Boende, Province de La Tshuapa, Democratic Republic of the Congo
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ebola vaccine in a nasal spray? early trial halted
- Ebola vaccine memory under the microscope: how long does it last?
- Could a vaccine and antibody combo stop ebola after exposure?
- UK volunteers test new ebola vaccine combo in Early-Stage trial
- Ebola antibody cocktail made available in emergency outbreak
- Hope in a pill? ebola drug favipiravir tested in guinea